Patents by Inventor Allan W. Rey

Allan W. Rey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200207761
    Abstract: The present invention provides a novel crystalline form of Valbenazine dibesylate, Valbenazine dibesylate Form APO-I, compositions and processes for the preparation thereof, and the use of this crystalline form in the treatment of hyperkinetic disorders, including tardive dyskinesia.
    Type: Application
    Filed: December 18, 2019
    Publication date: July 2, 2020
    Inventors: Mohammed Abdul Raheem, Yajun Zhao, Minh T. N. Nguyen, Mohamed Ibrahim Zaki, Jenny L. Gerster, Stuart P. Green, Allan W. Rey
  • Patent number: 10662178
    Abstract: The present invention provides a novel crystalline form of Olaparib comprising Olaparib and benzyl alcohol, compositions thereof, and the use of this crystalline form in the treatment of cancers, such as germline BRCA-mutated (gBRCAm) advanced ovarian cancer.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: May 26, 2020
    Assignee: Apotex Inc.
    Inventors: Allan W. Rey, Fabio E. S. Souza, Annyt Bhattacharyya, Bahareh Khalili
  • Patent number: 10632107
    Abstract: The present invention provides crystalline forms of Deutetrabenazine. Specific crystalline forms provided by the present invention include Deutetrabenazine Form APO-I, a co-crystal of Deutetrabenazine and quercetin, and Deutetrabenazine Form APO-II, a co-crystal of Deutetrabenazine and luteolin. Also provided are pharmaceutical compositions including the Deutetrabenazine crystalline forms, and the use of these forms in the treatment of tardive dyskinesia and chorea associated with Huntington's disease.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: April 28, 2020
    Assignee: Apotex Inc.
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Allan W. Rey
  • Publication number: 20200095255
    Abstract: The present invention provides novel crystalline forms of Ponatinib hydrochloride. Specific crystalline forms provided by the present invention include Ponatinib hydrochloride Form APO-I, APO-III and APO-IV, each of which is obtained from acetonitrile/formic acid solutions. Additionally, Form APO-V is provided, which is obtained from concentrated hydrochloric acid.
    Type: Application
    Filed: June 15, 2018
    Publication date: March 26, 2020
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Katherine A. Rantanen, Jenny L. Gerster, Annyt Bhattacharyya, Boris Gorin, Allan W. Rey
  • Publication number: 20190390235
    Abstract: The present invention provides processes for the preparation of Dasotraline, as well as intermediates useful in the preparation thereof. In particular, processes are provided for the enzymatic transamination of a compound of Formula (2) to afford Dasotraline.
    Type: Application
    Filed: June 12, 2019
    Publication date: December 26, 2019
    Inventors: Fabio E. S. Souza, Prabhudas Bodhuri, Eduardo Gustavo Cammisa, Gamini Weeratunga, Allan W. Rey
  • Patent number: 10513500
    Abstract: The present invention provides novel crystalline forms of Lesinurad, pharmaceutical compositions including these crystalline forms, and their use in the treatment of hyperuricemia associated with gout. Specific crystalline forms provided by the present invention include Lesinurad Forms APO-I, a hemi-methanolate, APO-II, a hemi-ethanolate, and APO-III, a co-crystal of Lesinurad and nicotinamide.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: December 24, 2019
    Assignee: Apotex Inc.
    Inventors: Jenny L. Gerster, Katherine A. Rantanen, Allan W. Rey
  • Publication number: 20190343815
    Abstract: The present invention provides crystalline forms of Deutetrabenazine. Specific crystalline forms provided by the present invention include Deutetrabenazine Form APO-I, a co-crystal of Deutetrabenazine and quercetin, and Deutetrabenazine Form APO-II, a co-crystal of Deutetrabenazine and luteolin. Also provided are pharmaceutical compositions including the Deutetrabenazine crystalline forms, and the use of these forms in the treatment of tardive dyskinesia and chorea associated with Huntington's disease.
    Type: Application
    Filed: May 13, 2019
    Publication date: November 14, 2019
    Inventors: Fabio E.S. Souza, Bahareh Khalili, Allan W. Rey
  • Patent number: 10407396
    Abstract: The present invention provides a novel crystalline form of Selexipag, Selexipag Form APO-I, which is a methanol solvate of Selexipag, compositions thereof, and the use of this crystalline form in the treatment of pulmonary arterial hypertension.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: September 10, 2019
    Assignee: Apotex Inc.
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Katherine A. Rantanen, Annyt Bhattacharyya, Jenny L. Gerster, Allan W. Rey
  • Publication number: 20190263760
    Abstract: The present invention provides novel crystalline forms of Lesinurad, pharmaceutical compositions including these crystalline forms, and their use in the treatment of hyperuricemia associated with gout. Specific crystalline forms provided by the present invention include Lesinurad Forms APO-I, a hemi-methanolate, APO-II, a hemi-ethanolate, and APO-III, a co-crystal of Lesinurad and nicotinamide.
    Type: Application
    Filed: November 9, 2017
    Publication date: August 29, 2019
    Inventors: Jenny L. Gerster, Katherine A. Rantanen, Allan W. Rey
  • Publication number: 20190233400
    Abstract: The present invention provides a novel crystalline form of Olaparib comprising Olaparib and benzyl alcohol, compositions thereof, and the use of this crystalline form in the treatment of cancers, such as germline BRCA-mutated (gBRCAm) advanced ovarian cancer.
    Type: Application
    Filed: January 30, 2019
    Publication date: August 1, 2019
    Inventors: Allan W. Rey, Fabio E. S. Souza, Annyt Bhattacharyya, Bahareh Khalili
  • Publication number: 20190144397
    Abstract: The present invention provides a novel crystalline form of Selexipag, Selexipag Form APO-I, which is a methanol solvate of Selexipag, compositions thereof, and the use of this crystalline form in the treatment of pulmonary arterial hypertension.
    Type: Application
    Filed: November 9, 2018
    Publication date: May 16, 2019
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Katherine A. Rantanen, Annyt Bhattacharyya, Jenny L. Gerster, Allan W. Rey
  • Patent number: 10183024
    Abstract: The present invention provides crystalline forms of Ibrutinib. Specific crystalline forms provided by the present invention include Ibrutinib Form APO-I, an anhydrous form; APO-II, a methyl benzoate solvate of Ibrutinib; and APO-IV, a methyl salicylate solvate of Ibrutinib.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: January 22, 2019
    Assignee: Apotex Inc.
    Inventors: Fabio E. S. Souza, Annyt Bhattacharyya, Bahareh Khalili, Allan W. Rey, Boris Gorin
  • Publication number: 20180153895
    Abstract: The present invention provides crystalline forms of Ibrutinib. Specific crystalline forms provided by the present invention include Ibrutinib Form APO-I, an anhydrous form; APO-II, a methyl benzoate solvate of Ibrutinib; and APO-IV, a methyl salicylate solvate of Ibrutinib.
    Type: Application
    Filed: November 30, 2017
    Publication date: June 7, 2018
    Inventors: Fabio E. S. Souza, Annyt Bhattacharyya, Bahareh Khalili, Allan W. Rey, Boris Gorin
  • Publication number: 20170291882
    Abstract: Solid forms of Mirabegron, including forms APO-I, APO-II, and various salt forms, and processes for the preparation thereof, are provided.
    Type: Application
    Filed: October 1, 2015
    Publication date: October 12, 2017
    Inventors: Allan W. Rey, Annyt Bhattacharyya, Jenny L. Gerster, Sammy Chris Duncan, Mohammed Abdul Raheem, Fan Wang, Stuart P. Green
  • Patent number: 9382233
    Abstract: Vilazodone hydrochloride benzyl alcohol solvates are provided as well as processes for the preparation thereof.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: July 5, 2016
    Assignee: Apotex Inc.
    Inventors: Gamini Weeratunga, Murali Kondamreddy, Allan W. Rey, Cameron L. McPhail, Yajun Zhao
  • Publication number: 20150175583
    Abstract: Vilazodone hydrochloride benzyl alcohol solvates are provided as well as processes for the preparation thereof.
    Type: Application
    Filed: June 13, 2013
    Publication date: June 25, 2015
    Inventors: Weeratunga Gamini, Murali Kondamreddy, Allan W. Rey, Cameron L. McPhail, Yajun Zhao
  • Patent number: 8883795
    Abstract: Provided for in the instant application are two additional polymorphic forms of rifaximin; namely substantially pure APO-I and APO-II. Also provided are processes for preparing substantially pure APO-I and APO-II. Rifaximin is a non-aminoglycoside antibiotic that has previously been found to be useful for the treatment of traveller's diarrhea caused by Escherichia coli bacteria, as well as in the treatment of irritable bowel syndrome, diverticular disease, hepatic encephalopathy, pyogenic skin infections and as an antibacterial prophylactic prior to colon surgery.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: November 11, 2014
    Assignee: Apotex Pharmachem Inc.
    Inventors: Kiran Kumar Kothakonda, Allan W. Rey
  • Patent number: 8471011
    Abstract: A process for the preparation of an acid addition salt of an organic base comprising exposing the organic base in solid form to a gaseous acid, with the proviso that ziprasidone, its acid addition salts and intermediates thereof are excluded.
    Type: Grant
    Filed: June 29, 2005
    Date of Patent: June 25, 2013
    Assignee: Apotex PharmaChem Inc.
    Inventors: Allan W. Rey, Lotfi Derdour, K. S. Keshava Murthy, Probal Kanti Datta, Martin Ehlert, Stephen E. Horne
  • Publication number: 20130090348
    Abstract: Provided for in the instant application are two additional polymorphic forms of rifaximin; namely substantially pure APO-I and APO-II. Also provided are processes for preparing substantially pure APO-I and APO-II. Rifaximin is a non-aminoglycoside antibiotic that has previously been found to be useful for the treatment of traveller's diarrhea caused by Escherichia coli bacteria, as well as in the treatment of irritable bowel syndrome, diverticular disease, hepatic encephalopathy, pyogenic skin infections and as an antibacterial prophylactic prior to colon surgery.
    Type: Application
    Filed: June 16, 2011
    Publication date: April 11, 2013
    Applicant: APOTEX PHARMACHEM INC.
    Inventors: Kiran Kumar Kothakonda, Allan W. Rey
  • Patent number: 8188300
    Abstract: Atorvastatin calcium propylene glycol solvates and processes to prepare these novel solvates which are particularly useful and suitable for pharmaceutical applications.
    Type: Grant
    Filed: November 15, 2010
    Date of Patent: May 29, 2012
    Assignee: Apotex Pharmachem Inc.
    Inventors: K.S. Keshava Murthy, Yajun Zhao, Allan W. Rey, Daqing Che, David A. Stradiotto, Uma Kotipalli